Cargando…
In Reply — COVID-19, the Female Immune Advantage, and Cardiovascular Impact
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Mayo Foundation for Medical Education and Research
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952147/ https://www.ncbi.nlm.nih.gov/pubmed/33673934 http://dx.doi.org/10.1016/j.mayocp.2020.12.020 |
| _version_ | 1783663662423080960 |
|---|---|
| author | Ritter, Oliver Kararigas, Georgios |
| author_facet | Ritter, Oliver Kararigas, Georgios |
| author_sort | Ritter, Oliver |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7952147 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Mayo Foundation for Medical Education and Research |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-79521472021-03-12 In Reply — COVID-19, the Female Immune Advantage, and Cardiovascular Impact Ritter, Oliver Kararigas, Georgios Mayo Clin Proc Letter to the Editor Mayo Foundation for Medical Education and Research 2021-03 2020-12-29 /pmc/articles/PMC7952147/ /pubmed/33673934 http://dx.doi.org/10.1016/j.mayocp.2020.12.020 Text en © 2020 Mayo Foundation for Medical Education and Research. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Ritter, Oliver Kararigas, Georgios In Reply — COVID-19, the Female Immune Advantage, and Cardiovascular Impact |
| title | In Reply — COVID-19, the Female Immune Advantage, and Cardiovascular Impact |
| title_full | In Reply — COVID-19, the Female Immune Advantage, and Cardiovascular Impact |
| title_fullStr | In Reply — COVID-19, the Female Immune Advantage, and Cardiovascular Impact |
| title_full_unstemmed | In Reply — COVID-19, the Female Immune Advantage, and Cardiovascular Impact |
| title_short | In Reply — COVID-19, the Female Immune Advantage, and Cardiovascular Impact |
| title_sort | in reply — covid-19, the female immune advantage, and cardiovascular impact |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952147/ https://www.ncbi.nlm.nih.gov/pubmed/33673934 http://dx.doi.org/10.1016/j.mayocp.2020.12.020 |
| work_keys_str_mv | AT ritteroliver inreplycovid19thefemaleimmuneadvantageandcardiovascularimpact AT kararigasgeorgios inreplycovid19thefemaleimmuneadvantageandcardiovascularimpact |